SURMOUNT-5

A Study of Tirzepatide Compared With Semaglutide in Participants With Obesity or Overweight

Patient / Population Intervention / Exposition Comparaison Critère de jugement

In 751 adults with obesity but without type 2 diabetes, tirzepatide reduced body weight at 72 weeks more than semaglutide (-20.2% vs -13.7%).

751

Schéma

Phase 3b, open-label, randomised active-controlled head-to-head trial

Critère

Percent change in body weight from baseline to week 72

Pertinence

RésultatTirzepatide superior: -20.2% (95% CI -21.4 to -19.1) vs semaglutide -13.7% (95% CI -14.9 to -12.6), difference ~-6.5 points (P<0.001); waist circumference also fell more (-18.4 vs -13.0 cm).

Aronne LJ, et al. N Engl J Med. 2025;393(1):26-36. 10.1056/NEJMoa2416394

Discussion et critique

Open-label design (no placebo/blinding) and an efficacy endpoint of weight rather than CV outcomes. First head-to-head RCT positioning tirzepatide as the more potent option for pharmacologic weight management in obesity without diabetes.